PE20070769A1 - Procedimiento para la produccion de una preparacion farmaceutica monofasica para la terapia oral de la hemorragia uterina disfuncional - Google Patents

Procedimiento para la produccion de una preparacion farmaceutica monofasica para la terapia oral de la hemorragia uterina disfuncional

Info

Publication number
PE20070769A1
PE20070769A1 PE2006001239A PE2006001239A PE20070769A1 PE 20070769 A1 PE20070769 A1 PE 20070769A1 PE 2006001239 A PE2006001239 A PE 2006001239A PE 2006001239 A PE2006001239 A PE 2006001239A PE 20070769 A1 PE20070769 A1 PE 20070769A1
Authority
PE
Peru
Prior art keywords
procedure
production
pharmaceutical preparation
dysfunctional uterine
oral therapy
Prior art date
Application number
PE2006001239A
Other languages
English (en)
Inventor
Doris Hubler
Sabine Fricke
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35229828&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20070769(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of PE20070769A1 publication Critical patent/PE20070769A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE CONTIENE: A) ETINILESTRADIOL EN 0.020 mg; B) 2 mg DE 17 ALFA-CIANOMETIL-17-BETA-HIDROXIESTRA-4,9-DIEN-3-ONA (DIENOGEST). REFERIDA TAMBIEN A UN METODO DE TRATAMIENTO DE LA COMPOSICION DE DOSIS DIARIAS DE 21, 22, 23, 24, 25 Y DOSIS DIARIAS LIBRES DE INGESTA DE 7, 6, 5, 4, 3 DE MODO QUE LA CANTIDAD TOTAL DE DIAS DE CICLO ES 28. DICHA COMPOSICION ES UTIL EN LA ANTICONCEPCION ORAL
PE2006001239A 2005-10-13 2006-10-12 Procedimiento para la produccion de una preparacion farmaceutica monofasica para la terapia oral de la hemorragia uterina disfuncional PE20070769A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05022318 2005-10-13
EP05024776A EP1774970A1 (de) 2005-10-13 2005-11-14 Verfahren zur Herstellung eines einphasigen pharmazeutischen Präparates zur Therapie der dysfunktionellen uterinen Blutung, enthaltend Ethinylestradiol und Dienogest

Publications (1)

Publication Number Publication Date
PE20070769A1 true PE20070769A1 (es) 2007-08-24

Family

ID=35229828

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006001239A PE20070769A1 (es) 2005-10-13 2006-10-12 Procedimiento para la produccion de una preparacion farmaceutica monofasica para la terapia oral de la hemorragia uterina disfuncional

Country Status (9)

Country Link
EP (2) EP1774970A1 (es)
JP (1) JP2009511512A (es)
AR (1) AR056581A1 (es)
CA (1) CA2624380A1 (es)
GT (1) GT200600459A (es)
PE (1) PE20070769A1 (es)
TW (1) TW200744609A (es)
UY (1) UY29860A1 (es)
WO (1) WO2007042110A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009049813A2 (de) * 2007-10-11 2009-04-23 Bayer Schering Pharma Aktiengesellschaft Verfahren zur herstellung eines einphasischen pharmazeutischen präparates zur begrenzung/minderung des risikos einer tiefen-venen-thrombose in einheit mit einer oralen kontrazeption
AT12800U1 (de) * 2007-11-05 2012-11-15 Bayer Schering Pharma Ag Pharmazeutisches Präparat zur Verwendung bei der oralen Kontrazeption von Frauen mit Laktoseintoleranz

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451778B1 (en) * 1996-07-26 2002-09-17 Wyeth Oral contraceptive
US6251956B1 (en) 1998-08-20 2001-06-26 Ortho Pharmaceutical Corporation Combination progestin oral contraceptive regimen
CA2372773A1 (en) * 1999-05-04 2000-11-09 American Home Products Corporation Contraceptive compositions containing antiprogestinic and progestinic
AU4813900A (en) * 1999-05-04 2000-11-17 American Home Products Corporation Contraceptive compositions containing indoline derivatives and progestational agents
JP2007528358A (ja) * 2003-06-25 2007-10-11 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト ジエノゲストを含んでなるホルモン置換療法および抑鬱療法
NZ585546A (en) * 2003-07-16 2011-10-28 Teva Womens Health Inc Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
US20050113350A1 (en) * 2003-11-26 2005-05-26 Bernd Duesterberg Extended use combination comprising estrogens and progestins
EP1535618A1 (en) * 2003-11-26 2005-06-01 Schering Aktiengesellschaft Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions
EP1690543A1 (de) * 2005-02-15 2006-08-16 Schering AG Pharmazeutisches Präparat zur Kontrazeption

Also Published As

Publication number Publication date
TW200744609A (en) 2007-12-16
EP1774970A1 (de) 2007-04-18
EP1937273A1 (de) 2008-07-02
GT200600459A (es) 2007-05-04
AR056581A1 (es) 2007-10-10
WO2007042110A1 (de) 2007-04-19
UY29860A1 (es) 2007-05-31
JP2009511512A (ja) 2009-03-19
CA2624380A1 (en) 2007-04-19

Similar Documents

Publication Publication Date Title
BRPI0513200A (pt) uso de um anticorpo anti-igf-1r na preparação de um medicamento para tratamento combinado para malignidades não-hematológicas
CO6150188A2 (es) Uso de teencteplasa para tratar un ictus isquemico agudo
AR045972A1 (es) Formulaciones de tramadol de liberacion sostenida con eficacia de 24 horas
BRPI0408256A (pt) composto, métodos de tratamento de um humano ou animal, pela limitação da replicação de células, que sofre de cáncer, que sofre de uma doença neoplástica, e que se sofre de doenças proliferativas, uso de um composto, e, processo para a preparação de um composto ou de um seu sal farmaceuticamente aceitável ou de um éster hidrolisável in vivo do mesmo
CO6270217A2 (es) Formulaciones galenicas de alisquireno y valsartan
PH12020551911A1 (en) Use of riluzole oral disintigrating tablets for treating diseases
PE20060124A1 (es) Tabletas de desintegracion que comprenden licarbazepina
PE20070769A1 (es) Procedimiento para la produccion de una preparacion farmaceutica monofasica para la terapia oral de la hemorragia uterina disfuncional
BR0308038A (pt) Ambroxol para o tratamento de estados doloridos na cavidade bucal e faringe
UY29861A1 (es) Uso de valerato de estradiol en combinación con dienogest para la terapia oral de la hemorragia uterina disfuncional unida con una anticoncepcion oral
AR049195A1 (es) Uso de una combinacion de etinilestradiol y acetato de clormadinona para la preparacion de un medicamento
NO20072687L (no) Farmasoytisk prevensjonspreparat
ATE259223T1 (de) Pharmazeutische zusammensetzung die einen no donor enthält und dessen therapeutische anwendung
AR062894A1 (es) Formulaciones para administracion terapeutica de hormona de estimulacion del tiroides (ths)
AR047154A1 (es) Tratamiento del insomnio en pacientes humanos administrandoles una cantidad diaria de gaboxadol
RU2539422C1 (ru) Способ лечения кариеса зубов
JP2019514978A5 (es)
CA2664300A1 (en) Agent for preventing onset of post-stroke reflex sympathetic dystrophy
CR10261A (es) Formulaciones novedosas
CY1112775T1 (el) Χρηση βαλεριανικης οιστραδιολης σε συνδυασμο με dienogest για την απο του στοματος θεραπεια της δυσλειτουργικης αιμορραγιας της μητρας σε ενοτητα με αντισυλληψη απο του στοματος
BRPI0509305A (pt) uso de um sensibilizador insulìnico, composição farmecêutica, e , kit
CO6150137A2 (es) Composicion farmaceutica que contiene bicalutamida y un metodo para su uso
RS50849B (sr) Upotreba estradiolvalerata i dienogesta za oralno lečenje disfunkcionalnog uterinog krvarenja u kontracepcijskom metodu
EA202092944A1 (ru) Применение пероральных распадающихся таблеток рилузола для лечения заболеваний
ATE403424T1 (de) Verwendung von zinkgluconat zur behandlung von hydradenitis suppurativa

Legal Events

Date Code Title Description
FC Refusal